Safety, Tolerability and Preliminary Efficacy of Multiple Intra-articular Injections of LRX712 in Patients With Knee OA
A legfontosabb adatok
- Ki végzi
- Novartis Pharmaceuticals
- Hol
- Hollandia1 helyszín, 1 országbanVálassz országot a helyszínekhez
- Azonosító
- Állapot
- Befejeződött
- Fázis
- 2. fázis
- Résztvevők
- 45 fő vett részt
- Kezdés
- 2020. júl. 20.
- Befejezés
- 2025. jan. 17.
- A vizsgálat típusa
- Beavatkozással járó, 4 csoportAz egyik csoport placebót (hatóanyag nélküli szert) kap, összehasonlításként.
- A vizsgált kezelések
- LRX712
- Placebo
- A regiszteradat frissítve
- 2026. január 30.
Ki vehet részt
- Életkor
- 35 év – 75 év
- Nem
- Nők és férfiak
- Egészséges önkéntesek
- Nem vehetnek részt
A regiszter feltételei, szó szerint
Mind a 16 feltétel megnézéseKevesebb
Ki vehet részt
- Written informed consent must be obtained before any assessment is performed
- To be eligible for inclusion in this study patients must meet all of the following criteria:
- Patient must have a BMI between 18 -35 kg/m2
- Patient must have symptomatic knee osteoarthritis predominantly in one knee (index knee)
- Patient must have knee osteoarthritis (Kellgren-Lawrence grade 2 or 3) in the index knee, as confirmed by radiography
- Patient must have radiographic confirmation of a medial joint space width of 1.5 to 3.5 mm for females, or 2 to 4 mm for males within the medial tibio-femoral compartment of the index knee
Ki nem vehet részt
- Previous use of LRX712 or use of other investigational drugs at the time of enrollment, or within 5 half-lives of enrollment, or within 30 days, whichever is longer; or longer if required by local regulations
- Signs or symptoms, in the judgment of the investigator, of a clinically significant systemic viral, bacterial or fungal infection within 30 days prior to screening; Other protocol-defined inclusion/exclusion criteria may apply
- Patient has a known autoimmune disease, inflammatory or chronic arthropathy other than OA
- History of significant cardiac conduction/electrophysiological disorder, e.g. familial long QT syndrome or known family history of Torsades de Pointes or prolonged QT syndrome or QTcF ≥ 450 msec (Fridericia Correction) for males and ≥ 460 msec for females at screening or baseline (by local 12-lead digitized ECG reading)
- Subjects meeting any of the following criteria are not eligible for inclusion in this study:
- Patient had partial or complete joint replacement in one or both knees
- Patient has symptomatic, isolated patello-femoral pain in the index knee as per the Investigator's examination
- Pregnant or nursing (lactating) women
- Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant
- Patient has malalignment (valgus- or varus-deformity) ≥ 7.5° in the index knee as per anatomic PA axis measured by weight-bearing short knee radiography
Hol van ez a vizsgálat?
Egy országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.
A vizsgálatról
Mit akar kideríteni a vizsgálat
This study explored the preliminary efficacy of multiple intra-articular injections of LRX712 by evaluating the ability of the drug to restore structural integrity of articular cartilage. Efficacy was evaluated in the context of the systemic safety and local tolerability of the investigational drug.
A vizsgálat 4 csoportja
- LRX712 15 mgA vizsgált kezelés
LRX712 15 mg was administered intra-articularly (i.a.) every four weeks, for a total of three administrations.
Kezelés: LRX712
- LRX712 25 mgA vizsgált kezelés
LRX712 25 mg was administered i.a. every four weeks, for a total of three administrations.
Kezelés: LRX712
- LRX712 75 mgA vizsgált kezelés
LRX712 75 mg was administered i.a. every four weeks, for a total of three administrations.
Kezelés: LRX712
- PlaceboPlacebo, összehasonlításként
Placebo was administered i.a. every four weeks, for a total of three administrations.
Adatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on.
- Hivatalos cím
- A Randomized, Placebo-controlled, Subject and Investigator Blinded Study Investigating the Safety, Tolerability and Preliminary Efficacy of 8-week Treatment With Intra-articular LRX712 to Regenerate Articular Cartilage in Patients With Mild/Moderate Knee Osteoarthritis
- A regiszteradat frissítve
- 2026. január 30.